EP2387997A1 — Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients who developed permanent atrial fibrillation throughout the period the dronedarone is administered
Assigned to Sanofi SA · Expires 2011-11-23 · 14y expired
What this patent protects
Use of dronedarone or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the prevention of cardiovascular events notably stroke, acute coronary syndrome or cardiovascular death in patients who developed permanent atrial fibrillation/flutter through…
USPTO Abstract
Use of dronedarone or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the prevention of cardiovascular events notably stroke, acute coronary syndrome or cardiovascular death in patients who developed permanent atrial fibrillation/flutter throughout the period the dronedarone or a pharmaceutically acceptable salt thereof is administered.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.